Oligomer Oy Company Profile

18:08 EDT 23rd June 2018 | BioPortfolio



Latokartanonkaari 11 D-talo


Phone: 358- 9- 3478 900
Fax: 358-9- 3478 9090

News Articles [6 Associated News Articles listed on BioPortfolio]

Distinct thermodynamic signatures of oligomer generation in the aggregation of the amyloid-β peptide

Cognition Therapeutics Initiates NIA-Funded SNAP Study of Elayta™ to Measure Toxic Oligomer Displacement and Clearance in Alzheimer's Disease

Pittsburgh, June 05, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheime...

Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer’s disease model

Oligomeric forms of amyloid-β (Aβ) and tau are increasing being recognized as key toxins in the pathogenesis of Alzheimer’s disease (AD).

Arcturus Therapeutics Announces Expansion of Collaboration with...

Arcturus Therapeutics Ltd. , a leading RNA medicines company, announced today that it is extending its partnership with Takeda Pharmaceutical Company Limited . Under the collaboration, Takeda and Arct...

Designer Multipass Transmembrane Proteins the Latest Cellwear

Transmembrane proteins from the House of Nature are abundant, but they’re all off the rack. Yes, they have been tailored to serve diverse functions, from transmembrane transport to cell signaling, b...

ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies

Humanized PMN310 Shows Significantly Greater Binding to The Toxic Oligomer Fraction of Alzheimer's Disease Brain Extract Compared to Aducanumab TORONTO and CAMBRIDGE, Mass., Jan. 23...

Drugs and Medications [0 Results]


PubMed Articles [74 Associated PubMed Articles listed on BioPortfolio]

Preparation of a Well-Defined and Stable β-Barrel Pore-Forming Aβ42 Oligomer.

The formation of amyloid-β peptide (Aβ) oligomers at the cellular membrane is considered a crucial process that underlies neurotoxicity in Alzheimer's disease (AD). To obtain structural information ...

DFT Modeling of Crosslinked Polyethylene: Role of Gold Atoms and Dispersion Interactions.

Using DFT modeling we analyze the concerted action of gold atoms and dispersion interactions in crosslinked polyethylene. Our model consists of two oligomer chains (PEn) with 7, 11, 15, 19 or 23 carbo...

Oligomeric Nucleants: Simulations of Chain Length, Binding Strength, and Volume Fraction Effects.

Recent theories and simulations suggest that molecular additives can bind to the surfaces of nuclei, lower the surface energy, and accelerate nucleation. Experiments have shown that oligomeric and pol...

Monomeric amyloid-β reduced amyloid-β oligomer-induced synapse damage in neuronal cultures.

Alzheimer's disease is a progressive neurodegenerative disease characterized by the accumulation of amyloid-β (Aβ) in the brain. Aβ oligomers are believed to cause synapse damage resulting in the m...

Hydrothermal Growth of Centimeter-Scale CuO Plates: Planar Chromium(III) Oligomer as a Facet-Directing Agent.

In this work, a simple hydrothermal method was developed to synthesize CuO plates in centimeter scale for the first time. Plates of up to 20 μm thickness and several square millimeters in area have b...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

This is a multi‐center, Phase 1b, randomized, double‐blind, placebo‐controlled parallel‐group trial in adults with mild to moderate AD.

Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid

AVI-4020 Injection, a phosphorodiamidate Morpholino oligomer (PMO), was found to cross the blood-brain barrier during a study of patients with presumptive West Nile virus disease. AVI-4065...

Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD), a fatal muscle degenerative disorder, arises from mutations in the dystrophin gene. Antisense therapy with the use of antisense oligonucleotides (AON) ha...

Companies [5 Associated Companies listed on BioPortfolio]

Oligomer Oy


Bio-Synthesis, Inc.

Bio-Synthesis Inc was the first commercial company providing DNA and peptides in 1984. We specialize in custom peptide synthesis from small to large scale and we can help you design the optimal pepti...


PolyMedix is the leader in developing biomimetics - novel small molecule, oligomer and polymer protein-mimetic drugs for membrane protein and protein:protein targets. PolyMedix has a proven computatio...

BioChrom Labs, Inc

Established in 1990, BioChrom Labs, Inc., Indiana, USA, is dedicated to developing and manufacturing polymeric materials using patentable and proprietary technologies. HYDROCELL HPLC Columns and packi...

Sarepta Therapeutics

Innovative RNA-Based Technology; First-in-Class Therapeutics Sarepta Therapeutics – formerly AVI BioPharma – remains focused on developing first-in-class, RNA-based therapeutics to imp...

More Information about "Oligomer Oy" on BioPortfolio

We have published hundreds of Oligomer Oy news stories on BioPortfolio along with dozens of Oligomer Oy Clinical Trials and PubMed Articles about Oligomer Oy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oligomer Oy Companies in our database. You can also find out about relevant Oligomer Oy Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record